Fubotv earnings beat by $0.10, revenue topped estimates
cbdMD (NYSE:YCBD), Inc. (NYSE American:YCBD), a North Carolina-based company specializing in perfumes, cosmetics, and other toilet preparations, disclosed on May 16, 2025, the issuance of restricted stock units (RSUs) to its board of directors. According to InvestingPro data, the company’s stock is currently trading at $0.94, showing significant potential based on its Fair Value analysis. The RSUs were awarded as part of the directors’ compensation for their service term starting April 11, 2025, coming at a time when the company faces challenging market conditions with a 73% decline over the past six months.
The company’s board, consisting of independent and non-management directors, each received 1,572 RSUs. These units are set to vest quarterly, with specific dates outlined as June 30, 2025, September 30, 2025, December 31, 2025, and March 31, 2026. The grants were made under cbdMD’s 2015 and 2021 Equity Compensation Plans, and the number of shares to be issued will be based on the closing price of the company’s common stock on the NYSE American LLC as of May 16, 2025.
In addition to the RSUs, cbdMD’s board approved annual fees for its independent directors. The fees include a $35,000 cash retainer payable monthly to each independent director, with additional payments for those serving in leadership roles. The Chairman of the Board will receive an extra $26,500, the Chairman of the Audit Committee will receive an additional $17,000, and the Chairman of the Compensation, Corporate Governance and Nominating Committee will get $7,000 more. Members of the Audit Committee and Compensation, Corporate Governance and Nominating Committee, excluding chairpersons, will receive an extra $8,500 and $4,000, respectively.
The information reported is based on a press release statement and is intended to provide shareholders and the investing public with a transparent view of the company’s governance and compensation practices. For deeper insights into cbdMD’s financial health and future prospects, InvestingPro subscribers have access to over 13 additional key insights and a comprehensive Pro Research Report, which provides detailed analysis of the company’s financial position and market performance.
In other recent news, cbdMD Inc. reported a significant improvement in its financial performance for the second quarter of 2025. The company achieved an 8.6% increase in total net sales year-over-year, reaching $4.7 million, with a notable 22% rise in wholesale sales. Despite a net loss of $480,000, this was a substantial improvement from the $3 million loss in the same period last year. cbdMD’s gross profit margin remained strong at 62%, and the company managed to reduce its selling, general, and administrative expenses to $3.5 million from $4.1 million in the prior year. Additionally, the company is exploring mergers and acquisitions as part of its growth strategy, aiming to enhance its market presence. Analysts from Maxim Group and Lismore Partners inquired about the impact of the Herbal Oasis brand on future revenues, with executives anticipating contributions beginning in late 2025. cbdMD’s recent capital restructuring, including the conversion of Series A preferred stock into common stock, has improved its financial flexibility and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.